Breast Cancer Research and Treatment

publication venue for

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. 201:257-264. 2023
Patient reported symptom burden amongst immigrant and Canadian long-term resident women undergoing breast cancer surgery. 199:553-563. 2023
A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. 193:1-20. 2022
Axillary surgery and complication rates after mastectomy and reconstruction for breast cancer: an analysis of the NSQIP database. 192:501-508. 2022
Comparison of upper extremity lymphedema after sentinel lymph node biopsy and axillary lymph node dissection: patient-reported outcomes in 3044 patients. 191:87-96. 2022
Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study. 189:797-806. 2021
DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS. 188:133-139. 2021
Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers. 188:343-350. 2021
Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey. 187:477-486. 2021
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. 187:515-523. 2021
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study. 187:759-768. 2021
A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients. 178:327-335. 2019
Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery. 178:169-176. 2019
Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients. 178:347-356. 2019
The time-varying effect of radiotherapy after breast-conserving surgery for DCIS. 178:221-230. 2019
Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis. 176:657-667. 2019
Body mass index impacts infection rates in immediate autogenous breast reconstruction. 175:765-773. 2019
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. 175:443-449. 2019
Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study. 175:721-731. 2019
Enhanced recovery after surgery (ERAS) pathways in breast reconstruction: systematic review and meta-analysis of the literature. 173:65-77. 2019
Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. 173:455-463. 2019
Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study. 171:709-717. 2018
Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis. 170:455-476. 2018
Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab. 170:169-177. 2018
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). 169:537-548. 2018
Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. 168:299-310. 2018
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.. 167:485-493. 2018
Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival. 172:123-132. 2018
Does obesity modify the relationship between physical activity and breast cancer risk?. 166:367-381. 2017
Ablative Therapies in Metastatic Breast Cancer: A Systematic Review. 164:13-25. 2017
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. 164:371-378. 2017
Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. 163:631-632. 2017
A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy. 163:11-19. 2017
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. 162:1-10. 2017
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. 161:117-134. 2017
A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women. 158:553-561. 2016
Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. 158:407-420. 2016
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. 157:109-116. 2016
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. 157:101-108. 2016
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. 156:343-349. 2016
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. 153:353-360. 2015
Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. 151:639-652. 2015
Erratum to: Platinum-based chemotherapy in triple-negative advanced breast cancer. 150:697-697. 2015
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. 150:605-611. 2015
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. 149:439-448. 2015
Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications. 149:293-301. 2015
Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review. 148:1-5. 2014
Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival. 146:583-589. 2014
Platinum-based chemotherapy in triple-negative advanced breast cancer. 146:567-572. 2014
Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer. 146:447-450. 2014
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. 146:421-427. 2014
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. 146:153-162. 2014
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. 144:615-624. 2014
Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials. 142:143-151. 2013
Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients. 140:577-585. 2013
Clinical–pathologic significance of cancer stem cell marker expression in familial breast cancers. 140:195-205. 2013
Erratum to: Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis. 139:295-300. 2013
Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. 138:581-590. 2013
Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study. 138:951-959. 2013
Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis. 137:783-795. 2013
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. 136:143-151. 2012
Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6. 136:117-127. 2012
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. 132:225-234. 2012
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. 131:541-551. 2012
Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. 130:133-143. 2011
Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice. 130:49-60. 2011
Amplification of the prolactin receptor gene in mammary lobular neoplasia. 128:31-40. 2011
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. 128:401-409. 2011
EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry. 127:831-839. 2011
Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?. 127:587-588. 2011
Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. 126:295-310. 2011
Erratum to: Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. 126:269-269. 2011
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. 126:215-220. 2011
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). 123:453-461. 2010
High levels of uPA and PAI-1 predict a good response to anthracyclines. 121:625-626. 2010
Severe prolonged cholestatic hepatitis caused by exemestane. 121:789-791. 2010
Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. 119:347-356. 2010
Prognosis of BRCA-associated breast cancer: a summary of evidence. 119:13-24. 2010
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. 117:183-191. 2009
Is red meat intake a risk factor for breast cancer among premenopausal women?. 117:1-8. 2009
High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. 114:517-525. 2009
Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?. 114:387-389. 2009
Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial. 110:337-342. 2008
HER2/neu in systemic therapy for women with breast cancer: a systematic review. 109:209-229. 2008
A Phase 2 study of perifosine in advanced or metastatic breast cancer. 108:87-92. 2008
Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19. 100:263-271. 2006
Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status. 99:309-311. 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. 99:295-300. 2006
Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study. 94:135-144. 2005
PEA3, AP-1, and a unique repetitive sequence all are involved in transcriptional regulation of the breast cancer-associated gene, mammaglobin. 89:289-296. 2005
Locally advanced breast cancer in octogenarian women. 89:81-90. 2005
Prognostic factors affecting the natural history of node-negative breast cancer. 89:35-45. 2005
Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ?. 87:265-272. 2004
Hormone Replacement Therapy after Treatment for Breast Cancer: Physicians' Attitudes towards Randomized Trials. 79:213-223. 2003
Estradiol Promotes Growth and Angiogenesis in Polyoma Middle T Transgenic Mouse Mammary Tumor Explants. 78:1-6. 2003
A Comparison of Risk Perception and Psychological Morbidity in Women with Ductal Carcinoma in situ and Early Invasive Breast Cancer. 77:285-293. 2003
Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. 74:65-76. 2002
Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. 73:161-175. 2002
Expression of Ets-related Transcription Factors and Matrix Metalloproteinase Genes in Human Breast Cancer Cells. 72:227-232. 2002
Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. 61:111-119. 2000
Multidisciplinary weight management in locoregional breast cancer: results of a phase II study. 48:53-64. 1998
A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. 44:211-215. 1997
An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. 44:201-210. 1997
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. 40:171-178. 1996
Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. 31:83-94. 1994
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. 30:179-195. 1994
A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer. 22:263-272. 1992
The efficacy of bone scanning in the follow-up of patients with operable breast cancer. 4:303-307. 1984
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32) 2023
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100) 2008
A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in elderly breast cancer patients 2007
Galactose oxidase Schiff's reactivity is higher in nipple aspirate fluid from cancerous breasts than from healthy patients 2007
How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12) 2007
Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node negative breast cancer 2007
Natural history of skeletal complications in patients receiving chemotherapy for breast cancer metastatic to bone 2007
Patients' disease and treatment parameters significantly affect survival in metastatic breast cancer 2007
Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment. 2007
A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCICCTG MA. 21: Results of an interim analysis 2007
A phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy 2006
Canadian clinical practice patterns survey of adjuvant therapies for breast cancer. 2006
Cognitive impairment associated with chemotherapy for breast cancer: A mechanistic cohort study. 2006
Correlation between 2 or 3 year (y) disease-free survival (DFS) and 5y overall survival (OS) in adjuvant systemic trials of early stage breast cancer. 2006
Evaluating the performance of risk assessment models in BRCA1 and BRCA2 mutation detection. 2006
Metformin lowers fasting insulin levels in nondiabetic hyperinsulinemic early stage breast cancer (BC) patients - results of a phase II study. 2006
The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. 2006
Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). 2006
Baseline radiological staging in primary breast cancer: impact of an educational intervention on adherence to published guidelines. 2005
Meta-analysis examining the efficacy of serotonin selective reuptake inhibitors in the treatment of women with hot flashes 2005
Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer. 2005
Complementary and alternative medicine use among patients with locally advanced breast cancer 2004
Effect of letrozole versus placebo on bone mineral density in women completing >= 5 years (yrs) of adjuvant tamoxifen: ncic ctg ma.17b 2004
Estimate of prognosis for node negative breast cancer patients is affected by survival analysis model. 2004
Phase II study of perifosine in metastatic or advanced breast cancer. 2004
Virtual wedge and intensity modulated radiotherapy reduce the magnitude of scattered radiation during adjuvant breast radiation. 2004
HER2 status: A Canadian experience of concordance between central and local testing laboratories 2003
Male breast cancer: why is the incidence increasing? 2003
Ten-year outcome of breast-conserving surgery (BCS) and radiotherapy (RT) in women with breast cancer (BC) and germline BRCA 1/2 mutations: results from an international collaboration 2003
The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for breast cancer (BC) 2003
Tissue microarrays: accurate assessment of protein and DNA targets requires 3 cores per tumor sample. 2003
Urgent genetic assessment (GA) in the management of newly diagnosed familial breast cancer (br ca) patients: a feasibility study 2003
A prospective comparison of positron emission tomography scanning, sentinel lymph node biopsy and axillary dissection in staging patients with early stage breast cancer. 2002
A randomized trial comparing CEF to CME in premenopausal women with node positive breast cancer: update of NCICCTG MA.5. 2002
Feasibility and responsiveness of utility measurement in breast cancer patients: a prospective study. 2002
Health related quality of life (HRQOL) and psychosocial status at diagnosis are not associated with disease-free or overall survival (DFS or OS) in T1-3, N0-1, M0 breast cancer (BC). 2002
NAT2 interactions on breast cancer risk: SULT1A1 and cooked meat. 2002
Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis. 2002
Risk of acute leukemia following adjuvant epirubicin-based adjuvant chemotherapy for breast cancer. 2001
Mechanisms involved in the metastasis of cancer to bone 1993
A RANDOMIZED TRIAL COMPARING 12 WEEKS WITH 36 WEEKS OF ADJUVANT CHEMOTHERAPY IN STAGE-II BREAST-CANCER 1988
HER-2/NEU ONCOGENE AS A PROGNOSTIC FACTOR IN NODE NEGATIVE BREAST-CANCER 1988
THE INFLUENCE OF EXOGENOUS HORMONES ON ESTROGEN AND PROGESTERONE RECEPTORS IN PRIMARY BREAST-CARCINOMA 1988
A DOUBLE ANTIBODY-RADIOIMMUNOASSAY (RIA) FOR MONITORING METASTATIC BREAST-CANCER 1987
CANCER-CHEMOTHERAPY AND THROMBOSIS 1987
ENDOCRINE ACTIONS OF TAMOXIFEN THERAPY IN PREMENOPAUSAL PATIENTS WITH BREAST-CANCER 1987
RADIOIMMUNOLOCALIZATION STUDIES IN PATIENTS WITH METASTATIC BREAST-CANCER USING INDIUM-111-LABELED MA5 MOUSE MONOCLONAL-ANTIBODIES DIRECTED AT THE EPITHELIAL MEMBRANE ANTIGEN COMPLEX (EMAC) 1987
IDENTIFICATION OF ANTIGENIC DETERMINANTS RECOGNIZED BY A MONOCLONAL-ANTIBODY PANEL PREPARED VERSUS BREAST-TUMOR MEMBRANES 1986
PHASE-I-II STUDY OF FLUTAMIDE IN METASTATIC BREAST-CANCER 1986
QUALITY-OF-LIFE IN STAGE-II BREAST-CANCER - AN INSTRUMENT FOR CLINICAL-TRIALS 1986
PROGNOSTIC FACTORS (PF) IN POSTMENOPAUSAL WOMEN WITH AXILLARY NODE POSITIVE BREAST-CANCER (AN+) 1985

Breast Cancer Research and Treatment Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)